Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series

Objectives. Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease with genetic predisposition and represents up to 10% of pediatric hemolytic uremic syndrome (HUS) cases. Few studies have evaluated aHUS in Latin American population. We studied a Colombian pediatric c...

Full description

Autores:
Espitaleta, Zilac
Domínguez-Vargas, Alex
Villamizar-Martínez, Johanna
Carrascal-Guzmán, Martha
Guerrero-Tinoco, Gustavo
Pinto-Bernal, Claudia
González-Chaparro, Luz
Rojas-Rosas, Luisa
Amado-Niño, Pilar
Castillo-Arteaga, Mariángel
Alvarez-Gómez, Yeferson
Arguello-Muñoz, Laura
Morales-Camacho, William
León-Guerra, Oscar
Egea, Eduardo
Galeano-Rodríguez, Ricardo
Quintero-Gómez, Ana
Aroca-Martínez, Gustavo
Musso, Carlos G.
Tipo de recurso:
Fecha de publicación:
2024
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
eng
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/14129
Acceso en línea:
https://hdl.handle.net/20.500.12442/14129
https://doi.org/10.1177/2333794X241231133
https://journals.sagepub.com/doi/10.1177/2333794X241231133
Palabra clave:
Pediatric atypical hemolytic uremic syndrome
Thrombotic microangiopathy
Extrarenal manifestations
Rights
openAccess
License
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
id USIMONBOL2_4a6a261a58f5b622d3163880dff5d7a5
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/14129
network_acronym_str USIMONBOL2
network_name_str Repositorio Digital USB
repository_id_str
dc.title.spa.fl_str_mv Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series
title Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series
spellingShingle Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series
Pediatric atypical hemolytic uremic syndrome
Thrombotic microangiopathy
Extrarenal manifestations
title_short Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series
title_full Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series
title_fullStr Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series
title_full_unstemmed Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series
title_sort Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series
dc.creator.fl_str_mv Espitaleta, Zilac
Domínguez-Vargas, Alex
Villamizar-Martínez, Johanna
Carrascal-Guzmán, Martha
Guerrero-Tinoco, Gustavo
Pinto-Bernal, Claudia
González-Chaparro, Luz
Rojas-Rosas, Luisa
Amado-Niño, Pilar
Castillo-Arteaga, Mariángel
Alvarez-Gómez, Yeferson
Arguello-Muñoz, Laura
Morales-Camacho, William
León-Guerra, Oscar
Egea, Eduardo
Galeano-Rodríguez, Ricardo
Quintero-Gómez, Ana
Aroca-Martínez, Gustavo
Musso, Carlos G.
dc.contributor.author.none.fl_str_mv Espitaleta, Zilac
Domínguez-Vargas, Alex
Villamizar-Martínez, Johanna
Carrascal-Guzmán, Martha
Guerrero-Tinoco, Gustavo
Pinto-Bernal, Claudia
González-Chaparro, Luz
Rojas-Rosas, Luisa
Amado-Niño, Pilar
Castillo-Arteaga, Mariángel
Alvarez-Gómez, Yeferson
Arguello-Muñoz, Laura
Morales-Camacho, William
León-Guerra, Oscar
Egea, Eduardo
Galeano-Rodríguez, Ricardo
Quintero-Gómez, Ana
Aroca-Martínez, Gustavo
Musso, Carlos G.
dc.subject.eng.fl_str_mv Pediatric atypical hemolytic uremic syndrome
Thrombotic microangiopathy
Extrarenal manifestations
topic Pediatric atypical hemolytic uremic syndrome
Thrombotic microangiopathy
Extrarenal manifestations
description Objectives. Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease with genetic predisposition and represents up to 10% of pediatric hemolytic uremic syndrome (HUS) cases. Few studies have evaluated aHUS in Latin American population. We studied a Colombian pediatric cohort to delineate disease presentation and outcomes. Methods. A multicenter cohort of 27 Colombian children with aHUS were included. Patients were grouped by age at onset. Clinical features were compared using analysis of variance (ANOVA) and Fisher exact tests. Renal biopsy was performed on 6 patients who were suspected of having other renal diseases before aHUS diagnosis. Results. Most patients were male (70%). The onset of aHUS occurred frequently before age 4 years (60%) and followed gastroenteritis as the main triggering event (52%). Age groups showed comparable clinical presentation, disease severity, treatment, and outcomes. Pulmonary involvement (67%) was the main extrarenal manifestation, particularly in the 1 to 7 age group (P = .01). Renal biopsies were as follows: 3 had membranoproliferative glomerulonephritis (MPGN) type I, one MPGN type III, one C3-glomerulonephritis, and one rapidly progressive GN. Genetic screening was available in 6 patients and identified 2xCFHR5, 2xMCP, 1xADAMTS13/ THBD, and 1xDGKE mutations. A total of 15 relapses were seen, of which 8 (72%) occurred in the 1 to 7 age group. The renal outcome was not significantly different regardless of age group. Conclusion. In our cohort, we observed a relatively high frequency of extrarenal involvement at first presentation represented by pulmonary manifestations. The renal prognosis at initial presentation was worse than in previous reports.
publishDate 2024
dc.date.accessioned.none.fl_str_mv 2024-02-14T16:18:05Z
dc.date.available.none.fl_str_mv 2024-02-14T16:18:05Z
dc.date.issued.none.fl_str_mv 2024
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.spa.spa.fl_str_mv Artículo científico
dc.identifier.issn.none.fl_str_mv 2333794X (Electrónico)
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12442/14129
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1177/2333794X241231133
dc.identifier.url.none.fl_str_mv https://journals.sagepub.com/doi/10.1177/2333794X241231133
identifier_str_mv 2333794X (Electrónico)
url https://hdl.handle.net/20.500.12442/14129
https://doi.org/10.1177/2333794X241231133
https://journals.sagepub.com/doi/10.1177/2333794X241231133
dc.language.iso.eng.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.eng.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.spa.fl_str_mv pdf
dc.publisher.eng.fl_str_mv Sage
dc.source.eng.fl_str_mv Global Pediatric Health
dc.source.none.fl_str_mv Vol. 11 Año (2024)
institution Universidad Simón Bolívar
bitstream.url.fl_str_mv https://bonga.unisimon.edu.co/bitstreams/f463c0ea-00fa-4f7b-9ef1-1ba55c101cd2/download
https://bonga.unisimon.edu.co/bitstreams/2dce72b2-95d9-4357-a6d6-647d1d79fbb5/download
https://bonga.unisimon.edu.co/bitstreams/868297fb-147b-4cf2-8a80-07d6a1fde9df/download
https://bonga.unisimon.edu.co/bitstreams/df0f8762-4e27-4511-b063-dcabe5094ecf/download
https://bonga.unisimon.edu.co/bitstreams/f995f596-f5fd-4fe9-b63e-bffaba601af8/download
https://bonga.unisimon.edu.co/bitstreams/f81e8c7a-adc6-4a18-b90e-5b8c960d3f8d/download
https://bonga.unisimon.edu.co/bitstreams/180d243c-994b-4750-8500-34545c8d2edc/download
bitstream.checksum.fl_str_mv 3375130d3aac49c508db7f47be8bdacd
4460e5956bc1d1639be9ae6146a50347
733bec43a0bf5ade4d97db708e29b185
03dbb12eba065d50a9a0902ab34dd627
03dbb12eba065d50a9a0902ab34dd627
9be008c230b4be33ab37634725ee9b24
9be008c230b4be33ab37634725ee9b24
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv repositorio.digital@unisimon.edu.co
_version_ 1812100493556580352
spelling Espitaleta, Zilac444ae19d-81a9-4686-821f-ce6dc31b4fa9Domínguez-Vargas, Alexd3599d9a-0024-4ac5-9bfb-269da6854041Villamizar-Martínez, Johannaa5f88b5d-ef85-4c88-adf1-3ed79815f06fCarrascal-Guzmán, Martha46d213c4-f883-4162-98c6-f9a7d207de90Guerrero-Tinoco, Gustavoe6a1bc89-7e66-4ef2-adf8-565f4f628a2cPinto-Bernal, Claudia12294b48-a846-4349-8ba0-a4eeb6690943González-Chaparro, Luzc09d89d1-358a-4172-a6fe-b14baaf05de3Rojas-Rosas, Luisa9ad94c36-73b7-4543-a885-f33fd500070cAmado-Niño, Pilar7779f5d1-b64d-4617-a9ef-59838910841dCastillo-Arteaga, Mariángelb92d9444-809a-4f10-89cf-f87db11c48dbAlvarez-Gómez, Yefersonc321f0c2-3282-4fa9-b4fc-afa4959a9625Arguello-Muñoz, Laura0050c1b0-3a6d-43d6-9799-a3c9ebd306eeMorales-Camacho, Williamd774107d-1494-4cf6-8256-b024419c4010León-Guerra, Oscar4c12995f-baa1-4715-9b9f-87a37653e9d5Egea, Eduardo4f89b318-81b2-4eff-af87-ea8302a1d867Galeano-Rodríguez, Ricardo170974ec-67ec-4d48-bcaf-f8e55032f508Quintero-Gómez, Ana6937bd81-287f-445f-bd17-8f5bd68cffe4Aroca-Martínez, Gustavoef65933f-3af8-4323-9a75-9d00de17e70aMusso, Carlos G.b310094b-baeb-4838-bde5-206ff47448242024-02-14T16:18:05Z2024-02-14T16:18:05Z20242333794X (Electrónico)https://hdl.handle.net/20.500.12442/14129https://doi.org/10.1177/2333794X241231133https://journals.sagepub.com/doi/10.1177/2333794X241231133Objectives. Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease with genetic predisposition and represents up to 10% of pediatric hemolytic uremic syndrome (HUS) cases. Few studies have evaluated aHUS in Latin American population. We studied a Colombian pediatric cohort to delineate disease presentation and outcomes. Methods. A multicenter cohort of 27 Colombian children with aHUS were included. Patients were grouped by age at onset. Clinical features were compared using analysis of variance (ANOVA) and Fisher exact tests. Renal biopsy was performed on 6 patients who were suspected of having other renal diseases before aHUS diagnosis. Results. Most patients were male (70%). The onset of aHUS occurred frequently before age 4 years (60%) and followed gastroenteritis as the main triggering event (52%). Age groups showed comparable clinical presentation, disease severity, treatment, and outcomes. Pulmonary involvement (67%) was the main extrarenal manifestation, particularly in the 1 to 7 age group (P = .01). Renal biopsies were as follows: 3 had membranoproliferative glomerulonephritis (MPGN) type I, one MPGN type III, one C3-glomerulonephritis, and one rapidly progressive GN. Genetic screening was available in 6 patients and identified 2xCFHR5, 2xMCP, 1xADAMTS13/ THBD, and 1xDGKE mutations. A total of 15 relapses were seen, of which 8 (72%) occurred in the 1 to 7 age group. The renal outcome was not significantly different regardless of age group. Conclusion. In our cohort, we observed a relatively high frequency of extrarenal involvement at first presentation represented by pulmonary manifestations. The renal prognosis at initial presentation was worse than in previous reports.pdfengSageAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Global Pediatric HealthVol. 11 Año (2024)Pediatric atypical hemolytic uremic syndromeThrombotic microangiopathyExtrarenal manifestationsAtypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Seriesinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/resource_type/c_2df8fbb1Zipfel PF, Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens. 2010;19(4):372-378. doi:10.1097/ MNH.0b013e32833aff4aNoris M, Remuzzi G. Atypical hemolytic-uremic syndrome. New Engl J Med. 2009;361(17):1676-1687. doi:10.1056/NEJMra0902814Kurosawa S, Stearns-Kurosawa DJ. Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care. 2014;2(1):65. doi:10.1186/ s40560-014-0061-4Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295-305. doi:10.2147/CLEP.S245642Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859. doi:10.2215/ CJN.02210310Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(2):555-563. doi:10.1681/ASN.2004050380Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2014;25(1):55-64. doi:10.1681/ASN.2013050453Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-1279. doi:10.1182/blood-2005-10-007 252Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic- uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4- 21. doi:10.1111/1744-9987.12763Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol. 2001;12(2):297-307. doi:10.1681/ASN.V122297Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide french series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562. doi:10.2215/ CJN.04760512Kavanagh D, Richards A, Noris M, et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol. 2008;45(1):95-105. doi:10.1016/j.molimm.2007.05.004Goicoechea de, Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA. 2007;104(1):240-245. doi:10.1073/pnas.0603420103Frémeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008; 112(13):4948-4952. doi:10.1182/blood-2008-01-133702Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. New Engl J Med. 2009;361(4):345-357. doi:10.1056/NEJMoa 0810739Munoz J. Therapeutic apheresis procedures: mechanisms of action and immunomodulatory effects. ISBT Sci Ser. 2008;3(1):95-103. doi:10.1111/j.1751-2824.20 08.00178.xMills MC, Rahal C. A scientometric review of genomewide association studies. Commun Biol. 2019;2(1):9. doi:10.1038/s42003-018-0261-xJiménez-Kaufmann A, Chong AY, Cortés A, et al. Imputation performance in Latin American populations: improving rare variants representation with the inclusion of Native American genomes. Front Genet. 2021;12:719791- 719811. doi:10.3389/fgene.2021.719791Homburger JR, Moreno-Estrada A, Gignoux CR, et al. Genomic insights into the ancestry and demographic history of South America. PLoS Genet. 2015;11(12):e10056 02-e1005626. doi:10.1371/journal.pgen.1005602Conley AB, Rishishwar L, Norris ET, et al. A comparative analysis of genetic ancestry and admixture in the Colombian populations of chocó and Medellín. G3 Genes Genome Genet. 2017;7(10):3435-3447. doi:10.1534/g3.117.1118Geerdink LM, Westra D, van Wijk JA, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol. 2012;27(8):1283-1291. doi:10.1007/s00467-012-2131-yCórdoba JP, Contreras KM, Larrarte C, et al. Síndrome hemolítico urémico atípico, revisión de la literatura y documento de consenso. Enfoque diagnóstico y tratamiento. Rev Colomb Nefrol. 2015;2(1):19-40.Rondeau E, Cataland SR, Al-Dakkak I, et al. Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep. 2019;4(11):1568-1576. doi:10.1016/j.ekir.2019.07.016Brodsky RA. Eculizumab and aHUS: to stop or not. Blood. 2021;137(18):2419-2420. doi:10.1182/blood.202 0010234R Core Team. R: A Language and Environment for Statistical Computing. Published online 2015.Zhao J, Wu H, Khosravi M, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011;7(5):e1002079. doi:10.1371/journal.pgen.1002079Manenti L, Gnappi E, Vaglio A, et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant. 2013;28(9):2246-2259. doi:10.1093/ndt/ gft220Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol. 2019;34(8):1337-1348. doi:10.1007/s00467-018- 4039-7Schaefer F, Ardissino G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408-418. doi:10.1016/j.kint.2018.02.029Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97. doi:10.3389/fped.2014 .00097Cabarcas-Barbosa O, Aroca-Martínez G, Musso CG, et al. Atypical hemolytic uremic syndrome in the Colombian Caribbean: its particular characteristics. Int Urol Nephrol. 2022;54(6):1323-1330. doi:10.1007/s11255-021-03011-5Brackman D, Sartz L, Leh S, et al. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol Dial Transplant. 2011;26(10):3399-3403. doi:10.1093/ndt/gfr422Siegler RL, Brewer ED, Pysher TJ. Hemolytic uremic syndrome associated with glomerular disease. Am J Kidney Dis. 1989;13(2):144-147. doi:10.1016/s0272-6386(89)80133-7Dische FE, Culliford EJ, Parsons V. Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis. Br Med J. 1978;1(6120):1112-1113. doi:10.1136/ bmj.1.6120.1112Jha V, Murthy MS, Kohli HS, et al. Secondary membranoproliferative glomerulonephritis due to hemolytic uremic syndrome: an unusual presentation. Ren Fail. 1998;20(6):845-850. doi:10.3109/08860229809045182Licht C, Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb Haemost. 2009;101(2):271- 278. doi:10.1160/TH08-09-0575Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy. Nephrol Dial Transplant. 2016;31(5):717-725. doi:10.1093/ndt/gfu317Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol. 2019;34:1311-1323. doi:10.1007/s00467- 018-3989-0Józsi M, Barlow PN, Meri S. Editorial: function and dysfunction of complement factor H. Front Immunol. 2021;12:831044. doi:10.3389/fimmu.2021.831044Zhang Y, Ghiringhelli Borsa N, Shao D, et al. Factor H autoantibodies and complement-mediated diseases. Front Immunol. 2020;11:607211. doi:10.3389/fimmu.2020.60 7211Gatault P, Brachet G, Ternant D, et al. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. mAbs. 2015;7(6):1205-1211. doi:10.108 0/19420862.2015.1086049Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701-711. doi:10.1016/j.kint.2015.11.026ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf846175https://bonga.unisimon.edu.co/bitstreams/f463c0ea-00fa-4f7b-9ef1-1ba55c101cd2/download3375130d3aac49c508db7f47be8bdacdMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/2dce72b2-95d9-4357-a6d6-647d1d79fbb5/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/868297fb-147b-4cf2-8a80-07d6a1fde9df/download733bec43a0bf5ade4d97db708e29b185MD53TEXTespital2024-atypicemoluremromenationwcolompediatrseries.pdf.txtespital2024-atypicemoluremromenationwcolompediatrseries.pdf.txtExtracted texttext/plain42228https://bonga.unisimon.edu.co/bitstreams/df0f8762-4e27-4511-b063-dcabe5094ecf/download03dbb12eba065d50a9a0902ab34dd627MD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain42228https://bonga.unisimon.edu.co/bitstreams/f995f596-f5fd-4fe9-b63e-bffaba601af8/download03dbb12eba065d50a9a0902ab34dd627MD56THUMBNAILespital2024-atypicemoluremromenationwcolompediatrseries.pdf.jpgespital2024-atypicemoluremromenationwcolompediatrseries.pdf.jpgGenerated Thumbnailimage/jpeg6133https://bonga.unisimon.edu.co/bitstreams/f81e8c7a-adc6-4a18-b90e-5b8c960d3f8d/download9be008c230b4be33ab37634725ee9b24MD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg6133https://bonga.unisimon.edu.co/bitstreams/180d243c-994b-4750-8500-34545c8d2edc/download9be008c230b4be33ab37634725ee9b24MD5720.500.12442/14129oai:bonga.unisimon.edu.co:20.500.12442/141292024-08-14 21:53:14.35http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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